BRISTOL MYERS SQUIBB
- Country
- 🇺🇸United States
- Ownership
- -
- Established
- 1989-01-01
- Employees
- 30K
- Market Cap
- $97.5B
- Website
- https://www.bms.com/
A Phase II Dose Response Study in Japan in Chronic Hepatitis B
- First Posted Date
- 2009-12-01
- Last Posted Date
- 2010-02-02
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 120
- Registration Number
- NCT01022801
Multiple Ascending Dose Study of BMS-907351 (XL184) in Patients With Solid Tumors in Japan
- Conditions
- Neoplasms
- Interventions
- Drug: BMS-907351 (XL184)
- First Posted Date
- 2009-11-25
- Last Posted Date
- 2011-01-07
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 3
- Registration Number
- NCT01018745
- Locations
- 🇯🇵
Local Institution, Chuo-Ku, Tokyo, Japan
Hepatic Impaired Subjects Compared to Healthy Subjects Receiving Multi-dose BMS-650032
- First Posted Date
- 2009-11-25
- Last Posted Date
- 2011-10-26
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 28
- Registration Number
- NCT01019070
- Locations
- 🇺🇸
Advanced Clinical Res Inst, Anaheim, California, United States
🇺🇸Orlando Clinical Research Center, Orlando, Florida, United States
A Study in Japan of the Safety and Antiviral Activity With Chronic Hepatitis B Infection
- First Posted Date
- 2009-11-25
- Last Posted Date
- 2010-08-06
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 60
- Registration Number
- NCT01020565
Safety and Efficacy of Daclatasvir (BMS-790052) Plus Standard of Care in Japanese Patients (Pegylated-interferon Alpha-2a and Ribavirin)
- Conditions
- Hepatitis C Infection
- Interventions
- First Posted Date
- 2009-11-20
- Last Posted Date
- 2015-09-11
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 55
- Registration Number
- NCT01017575
- Locations
- 🇯🇵
Local Institution, Musashino-Shi, Tokyo, Japan
Study of MDX-1100 (Anti-CXCL10 Human Monoclonal Antibody) in Combination With Methotrexate in Subjects With Active Rheumatoid Arthritis (RA)
- First Posted Date
- 2009-11-20
- Last Posted Date
- 2010-04-23
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 70
- Registration Number
- NCT01017367
- Locations
- 🇷🇴
"Dr. Carol Davila" Central Military Emergency Clinical Hospital, Bucharest, Romania
🇺🇦Zaporizhya State Medical University, Department of Internal Diseases #2, Clinical facility: Medical and Sanitary Unit within the State-Owned Company "Radioprylad", Zaporizhya, Ukraine
🇷🇴"Sf. Pantelimon" Emergency Clinical Hospital, Bucharest, Romania
Safety and Efficacy of Daclatasvir (BMS-790052) Plus Standard of Care (Pegylated-interferon Alpha-2b and Ribavirin) in Japanese Patients
- Conditions
- Hepatitis C Infection
- Interventions
- First Posted Date
- 2009-11-20
- Last Posted Date
- 2015-10-12
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 51
- Registration Number
- NCT01016912
- Locations
- 🇯🇵
Local Institution, Minato-Ku, Tokyo, Japan
Study to Determine the Effectiveness of Antiviral Combination Therapy to Treat Hepatitis C Virus (HCV) Infected Patients Who Have Previously Failed Standard of Care
- Conditions
- Chronic Hepatitis C
- Interventions
- First Posted Date
- 2009-11-13
- Last Posted Date
- 2015-10-09
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 215
- Registration Number
- NCT01012895
- Locations
- 🇺🇸
Advanced Clinical Research Institute, Anaheim, California, United States
🇺🇸Mercy Medical Center, Baltimore, Maryland, United States
🇺🇸Carolinas Center For Liver Disease, Statesville, North Carolina, United States
Roll-Over Protocol To Provide Atv And/Or Truvada For Extended Access
- Conditions
- HIV
- Interventions
- First Posted Date
- 2009-10-29
- Last Posted Date
- 2017-05-11
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 710
- Registration Number
- NCT01003990
- Locations
- 🇵🇷
Clinical Research Puerto Rico, Inc., San Juan, Puerto Rico
🇺🇸Sbma Research, Llc, Miami Beach, Florida, United States
🇺🇸St Francis Memorial Hospital, San Francisco, California, United States
Efficacy, Pharmacokinetics, Safety, and Immunogenicity Study of Abatacept Administered Subcutaneously to Treat Rheumatoid Arthritis in Japanese Patients
- Conditions
- Rheumatoid Arthritis
- Interventions
- First Posted Date
- 2009-10-27
- Last Posted Date
- 2014-02-06
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 118
- Registration Number
- NCT01001832
- Locations
- 🇯🇵
Local Institution, Shinjuku-Ku, Tokyo, Japan